ACADIA Pharmaceuticals Inc. Book Value per Share Growth

Book Value per Share Growth of ACAD for past 10 years: annual, quarterly and twelve month trailing (TTM) including Book Value per Share Growth growth rates and interactive chart.


Highlights and Quick Summary

  • Book Value per Share Growth for the quarter ending March 30, 2021 was -11.54% (a -32.55% decrease compared to previous quarter)
  • Year-over-year quarterly Book Value per Share Growth decreased by -120.19%
  • Annual Book Value per Share Growth for 2020 was -16.09% (a -163.12% decrease from previous year)
  • Annual Book Value per Share Growth for 2019 was 25.49% (a -33.6% decrease from previous year)
  • Annual Book Value per Share Growth for 2018 was 38.39% (a -198.74% decrease from previous year)
Visit stockrow.com/ACAD for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Book Value per Share Growth of ACADIA Pharmaceuticals Inc.

Most recent Book Value per Share Growthof ACAD including historical data for past 10 years.

Interactive Chart of Book Value per Share Growth of ACADIA Pharmaceuticals Inc.

ACADIA Pharmaceuticals Inc. Book Value per Share Growth for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 -11.54%
2020 -17.11% -12.34% 57.17% 41.41% -16.09%
2019 25.49% 164.31% 27.16% 19.15% 25.49%
2018 38.39% -41.98% -37.66% -35.16% 38.39%
2017 -38.88% -37.38% -5.78% -5.95% -38.88%
2016 125.4% 118.04% 41.53% 40.54% 125.4%
2015 -37.62% -32.07% -27.88% -27.62% -37.62%
2014 49.78% 64.48% 62.46% 288.59% 49.78%
2013 37.8% 516.26% 806.54% 204.33% 37.8%
2012 244.4% -38.52% -61.48% -56.07% 244.4%
2011 -41.8% 11944.44% 657.11% 308.53% -41.8%
2010 138.73% -100.89% -88.39% 138.73%

Business Profile of ACADIA Pharmaceuticals Inc.

Sector: Healthcare
Industry: Biotechnology
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; Trofinetide, a novel synthetic analog for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor for treating cognition and schizophrenia. It is also developing pimavanserin as a treatment for dementia-related psychosis and as an adjunctive treatment for schizophrenia; and pimavanserin as an adjunctive treatment for major depressive disorder. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.